In this study, we sought to identify an alternative pathway that is responsible for resistance to the PI3K inhibitors, copanlisib and duvelisib, in B- and T-cell lymphoma. This evidence concerns the gene PIK3CB and T-cell non-Hodgkin lymphoma.